Madrigal, Suzhou Ribo in license deal for liver‑disease programs
11/02/2026 10:10
Feb 11 (Reuters) - Madrigal Pharmaceuticals MDGL.O said on Wednesday it has signed an exclusive global license agreement with China-based Suzhou Ribo Life Science 6938.HK and its subsidiary Ribocure Pharmaceuticals for six preclinical small interfering RNA programs to treat a type of liver disease. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on Suzhou Ribo Life Science
See all newsBrief: Suzhou Ribo Life Science To Buy Remaining 49.71% Of Target Company
Suzhou Ribo climbs on EU clinical trials application of RBD3133 for obesity
Brief: Suzhou Ribo Life Science Expects Revenue Of RMB311 Million-RMB436 Million For Six Months
Brief: Suzhou Ribo Life Science Says EMA Approves Initiation Of Phase 2B Trial Of Vortosiran
CEO Purchases 6800 H Shares On Open Market